<p>On days 0–4 and 7–11, BALB/c mice were daily received PBS, recombinant or wild-type <i>L. lactis</i> via the oral route. On days 17, 24 and 31, mice underwent intraperitoneal (i.p.) injection sensitization with the mixture of Der p2/Alum or sterile PBS. From day 39 to 43, all groups were inhalation challenged with aerosolized HDM allergen over a 45-min period. Positive and Negative group served as positive and negative control in this study, respectively.</p
<p>(<b>A</b>) Protocol followed in B–F: mice received Ad/GM-CSF or PBS 24 h prior to HDM exposure fo...
<p>BALB/c mice received intranasal HDM on 5 consecutive days per week for up to 5 consecutive weeks....
<p>Mice were sensitised to OVA by three intraperitoneal (i.p.) injections on days 0, 14 and 21 with ...
<p>The OVA-sensitized and challenged group: mice were sensitized on days 1, 3, 5, 7, 9, 11 and 13 by...
<p>BALB/c mice (11–13 per group) were sensitized by intranasal administration of 100 µg of ovalbumin...
In vivo animal models can provide worthy information on various aspects of asthma mechanism and path...
In vivo animal models can provide worthy information on various aspects of asthma mechanism and path...
<p>For sensitization, BALB/c mice received an i.p injection of OVA or PBS with aluminum hydroxide on...
<p>(A) Δ<sup>12</sup>-PGJ<sub>3</sub> (0.025 mg/kg body weight) was injected intraperitoneally into ...
<p>At 7 days after the last allergen sensitization, mice were challenged by allergen, followed by co...
<p>Mice were sensitized by i.p. administration of 2 µg ovalbumin admixed with 100 µl alum at day 0 a...
<p>pVAX-Der f1 or pCMV-βgal plasmid were injected i.m at days −28 and −7. Mice were then epicutaneou...
<p>BALB/c mice were sensitized with 0.05% OVA and 2% aluminum hydroxide (Alum) solution by intraperi...
<p>Mice were sensitized by two injections of OVA/alum and challenged by exposure to aerosols of alle...
<p><i>A</i>: Protocol 1: Re-Exposure Study: Mice were sensitized to HDM by 3 i.p. injections followe...
<p>(<b>A</b>) Protocol followed in B–F: mice received Ad/GM-CSF or PBS 24 h prior to HDM exposure fo...
<p>BALB/c mice received intranasal HDM on 5 consecutive days per week for up to 5 consecutive weeks....
<p>Mice were sensitised to OVA by three intraperitoneal (i.p.) injections on days 0, 14 and 21 with ...
<p>The OVA-sensitized and challenged group: mice were sensitized on days 1, 3, 5, 7, 9, 11 and 13 by...
<p>BALB/c mice (11–13 per group) were sensitized by intranasal administration of 100 µg of ovalbumin...
In vivo animal models can provide worthy information on various aspects of asthma mechanism and path...
In vivo animal models can provide worthy information on various aspects of asthma mechanism and path...
<p>For sensitization, BALB/c mice received an i.p injection of OVA or PBS with aluminum hydroxide on...
<p>(A) Δ<sup>12</sup>-PGJ<sub>3</sub> (0.025 mg/kg body weight) was injected intraperitoneally into ...
<p>At 7 days after the last allergen sensitization, mice were challenged by allergen, followed by co...
<p>Mice were sensitized by i.p. administration of 2 µg ovalbumin admixed with 100 µl alum at day 0 a...
<p>pVAX-Der f1 or pCMV-βgal plasmid were injected i.m at days −28 and −7. Mice were then epicutaneou...
<p>BALB/c mice were sensitized with 0.05% OVA and 2% aluminum hydroxide (Alum) solution by intraperi...
<p>Mice were sensitized by two injections of OVA/alum and challenged by exposure to aerosols of alle...
<p><i>A</i>: Protocol 1: Re-Exposure Study: Mice were sensitized to HDM by 3 i.p. injections followe...
<p>(<b>A</b>) Protocol followed in B–F: mice received Ad/GM-CSF or PBS 24 h prior to HDM exposure fo...
<p>BALB/c mice received intranasal HDM on 5 consecutive days per week for up to 5 consecutive weeks....
<p>Mice were sensitised to OVA by three intraperitoneal (i.p.) injections on days 0, 14 and 21 with ...